Novel genetic medicine approach to treat orphan diseases with AAV vectors
Official title: Development of novel genetic medicine approaches to treat orphan diseases
Funded at Kinea Bio, INC. · NIH-11348921 · Data updated 2026-11-12
A NIH-funded project is testing new ways to deliver large therapeutic genes using AAV vectors to help people with muscular dystrophies caused by big gene mutations.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinea Bio, INC. NIH-funded |
| Lab location | 1 site (Mukilteo, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $796,218 |
| NIH project number | 5R44AR083801-03 |
| Project ID | NIH-11348921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with muscular dystrophy caused by large genes (e.g., DYSF, DMD) who may benefit from improved gene-delivery methods in future clinical trials.
✕Less likely to help
Patients with conditions not related to muscular dystrophy or who are not suited for AAV-based gene therapy may not benefit.
What this research studies
This project addresses the challenge of fitting large disease genes into AAV delivery by exploring full-length dysferlin and dystrophin delivery using dual AAV vectors that recombine into a complete gene. Researchers will test a novel strategy to improve expression and distribution of big genes after delivery, aiming for higher protein levels and better tissue targeting. The work will move from early development toward approaches that could be used in patients with muscular dystrophies in the future.
Why it matters
Potential benefit: If successful, this approach could enable effective gene therapy for muscular dystrophy patients who currently lack options due to gene size constraints.
How similar studies have gone: Previous mini-gene approaches showed partial rescue; this project builds on dual-vector strategies to achieve full-length protein expression.
Where this research is happening
-
Kinea Bio, INC.
Mukilteo, United States Active
Researchers
- Principal investigator: Childers, Martin K — Kinea Bio, INC.
- Study coordinator: Childers, Martin K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.